D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and commercial milestones DD01 is a GLP-1R/GCGR dual agonist in development for the ...

Full "IntellAsia: Resources" article